ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200’s Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease
October 11, 2023 07:05 ET
|
ZyVersa Therapeutics
Cholesterol accumulation in the kidneys' podocytes from impaired efflux out of cells is one of the hallmarks of kidney injury in chronic kidney disease.
ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues
October 04, 2023 07:05 ET
|
ZyVersa Therapeutics
Brain inflammation from traumatic injury releases proinflammatory cytokines that activate inflammasomes in the heart leading to damaging inflammation.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
September 27, 2023 07:07 ET
|
ZyVersa Therapeutics
Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment.ZyVersa is advancing a dynamic pipeline of drug candidates with...
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
September 22, 2023 06:35 ET
|
ZyVersa Therapeutics
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP.This study demonstrated that CKD-induced IL-1β...
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
September 12, 2023 06:30 ET
|
ZyVersa Therapeutics
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative (“CNS”) diseases, such as amyotrophic lateral sclerosis (“ALS”)This study showed that NLRP3...
ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results
August 21, 2023 16:15 ET
|
ZyVersa Therapeutics
Key Highlights: Advanced clinical development initiatives for Cholesterol Efflux Mediator™ VAR 200, with planned initiation of a Phase 2a clinical trial in diabetic kidney disease (DKD) in the...
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
July 24, 2023 08:00 ET
|
ZyVersa Therapeutics
WESTON, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing...
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
July 17, 2023 07:38 ET
|
ZyVersa Therapeutics
Liver fibrosis is a progressive form of chronic liver injury mediated by persistent NLRP3 inflammasome activation in liver cells called hepatic stellate cells (“HSCs”), which leads to the development...
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023
July 14, 2023 07:37 ET
|
ZyVersa Therapeutics
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and...
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
July 10, 2023 07:37 ET
|
ZyVersa Therapeutics
Mechanical stress on the heart, such as high blood pressure, initiates NLRP3-induced inflammation through heart-brain interactions, causing heart enlargement (hypertrophic heart disease) Mechanical...